questionText: To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the National Institute for Health and Care Excellence on the use of encorafenib in combination with cetuximab and chemotherapy as a first‑line treatment for patients with BRAF V600E‑mutated metastatic colorectal cancer, in light of the results of the phase III BREAKWATER trial.
heading: Bowel Cancer: Medical Treatments